Anticancer activity of N-(phenylacetyl) doxorubicin combined with folate-targeted PGA

Yaoxue Xuebao

Volumn 40, Issue 11, 2005, Pages 1046-1050

  Zhang, Qi ^a   Xiang, Guang Ya ^a   Long, Na ^a   Lin, Jia Liang ^a   Zeng, Fan Bo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antitumor activity; Doxorubicin; Folate targeted; Penicillin G amidase

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CARRIER PROTEIN; CELL SURFACE RECEPTOR; DOXORUBICIN; DRUG DERIVATIVE; FOLATE BINDING PROTEIN; FOLATE RECEPTOR; FOLATE-BINDING PROTEIN; FOLIC ACID; PENICILLIN AMIDASE; PRODRUG;

ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; HELA CELL; HUMAN; IC 50; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CARRIER PROTEINS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; OVARIAN NEOPLASMS; PENICILLIN AMIDASE; PRODRUGS; RECEPTORS, CELL SURFACE;

EID: 29744448007     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs [J]. Pharmacol Rev, 2004,56(1):53-102.
2. Wang WG, Zhen YS. Antibody based targeting therapy and gene therapy of cancer [J]. Acta Pharm Sin, 1999,34(10);795-800.
3. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases [J]. Adv Drug Deliv Rev, 2004,56(8):1055-1058.
4. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents [J]. Adv Drug Deliv Rev, 2002,54(5):675-693.
5. Vrudhula VM, Senter PD, Fischer KJ, et al. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate [J]. J Med Chem, 1993,36(7):919-923.
6. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis [J]. Proc Natl Acad Sci USA, 1991,88 (13):5572-5576.
7. Lu JY, Lowe DA, Kennedy MD, et al. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug [J]. J Drug Target, 1999,7(1):43-53.
8. Lowe DA, Romancik G, Elander RP. Enzymatic hydrolysis of penicillin V to 6-aminopenicillanic acid by fusarium oxysporum [J]. Biotechnol Lett, 1986,8(3): 151-156.
9. Leamon CP, Reddy JA. Folate-targeted chemotherapy [J]. Adv Drug Deliv Rev, 2004,56(8):1127-1141.
10. Leamon CP, DePrince RB, Hendren RW. Folate-mediated drug delivery: effect of alternative conjugation chemistry [J]. J Drug Target, 1999,7(3):157-169.
11. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease [J]. Oncologist, 2002,7(Suppl 5):20-28.
12. Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer [J]. Oncologist, 2002,7(Suppl 5):11-19.
13. Leamon CP, Pastan I, Low PS. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain [J]. J Biol Chem, 1993,268(33):24847-24854.
14. Miotti S, Bagnoli M, Ottone F, et al. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines [J]. J Cell Biochem, 1997, 65(4):479-491.
15. Atkinson SF, Bettinger T, Seymour LW, et al. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells [J]. J Biol Chem, 2001,276(30):27930-27935.